MY110205A - Imidazolyl-alkenoic acids. - Google Patents
Imidazolyl-alkenoic acids.Info
- Publication number
- MY110205A MY110205A MYPI92001466A MYPI19921466A MY110205A MY 110205 A MY110205 A MY 110205A MY PI92001466 A MYPI92001466 A MY PI92001466A MY PI19921466 A MYPI19921466 A MY PI19921466A MY 110205 A MY110205 A MY 110205A
- Authority
- MY
- Malaysia
- Prior art keywords
- imidazolyl
- alkenoic acids
- receptor
- antagonisys
- angiotension
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/746,262 US5185351A (en) | 1989-06-14 | 1991-08-14 | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY110205A true MY110205A (en) | 1998-02-28 |
Family
ID=25000103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI92001466A MY110205A (en) | 1991-08-14 | 1992-08-14 | Imidazolyl-alkenoic acids. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5185351A (en:Method) |
| EP (1) | EP0641203B1 (en:Method) |
| JP (1) | JPH07500579A (en:Method) |
| CN (1) | CN1036396C (en:Method) |
| AP (3) | AP525A (en:Method) |
| AT (1) | ATE226073T1 (en:Method) |
| AU (1) | AU667824B2 (en:Method) |
| BG (1) | BG61593B1 (en:Method) |
| BR (1) | BR9206443A (en:Method) |
| CA (1) | CA2115170C (en:Method) |
| CZ (1) | CZ281635B6 (en:Method) |
| DE (1) | DE69232817T2 (en:Method) |
| DK (1) | DK0641203T3 (en:Method) |
| ES (1) | ES2185617T3 (en:Method) |
| FI (1) | FI114796B (en:Method) |
| HU (1) | HU225048B1 (en:Method) |
| IL (1) | IL102813A (en:Method) |
| MA (1) | MA22626A1 (en:Method) |
| MX (1) | MX9204737A (en:Method) |
| MY (1) | MY110205A (en:Method) |
| NO (1) | NO305172B1 (en:Method) |
| NZ (1) | NZ243966A (en:Method) |
| OA (1) | OA09884A (en:Method) |
| PL (1) | PL177234B1 (en:Method) |
| PT (1) | PT100779B (en:Method) |
| RO (1) | RO113643B1 (en:Method) |
| RU (1) | RU2124513C1 (en:Method) |
| SK (1) | SK281252B6 (en:Method) |
| TW (1) | TW234690B (en:Method) |
| UA (1) | UA40587C2 (en:Method) |
| WO (1) | WO1993003722A1 (en:Method) |
| ZA (1) | ZA926133B (en:Method) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| US5418250A (en) * | 1989-06-14 | 1995-05-23 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| US6034114A (en) * | 1990-12-14 | 2000-03-07 | Smithkline Beecham Plc | Medicament |
| US6028091A (en) * | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
| US6025380A (en) * | 1990-12-14 | 2000-02-15 | Smithkline Beecham Plc | Medicament |
| GB9027200D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| AU9137791A (en) * | 1990-12-14 | 1992-07-08 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| US5447949A (en) * | 1991-05-15 | 1995-09-05 | Smithkline Beecham Corporation | N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity |
| US20030166700A1 (en) * | 1991-12-12 | 2003-09-04 | Smithkline Beecham P.L.C. | Medicament |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| DE4206043A1 (de) * | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl-substituierte imidazole |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
| US5395847A (en) * | 1993-12-02 | 1995-03-07 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| NZ285588A (en) * | 1994-05-20 | 1997-12-19 | Smithkline Beecham Corp | [2-butyl-3-(4-carboxybenzyl)-1h-imidazolium-4-yl]-hydroxymethyl sulphonate |
| BR9508178A (pt) * | 1994-06-29 | 1997-11-18 | Smithkline Beecham Corp | Antagonistas de receptor de vitronectina |
| US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US6613789B2 (en) | 1994-07-28 | 2003-09-02 | G. D. Searle & Co. | Heterocyclo-substituted imidazoles for the treatment of inflammation |
| US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
| US6420412B2 (en) | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
| NZ332008A (en) * | 1996-03-29 | 1999-05-28 | Smithkline Beecham Corp | Eprosartan dihydrate and a process for its production and formulation |
| AR011126A1 (es) * | 1997-02-14 | 2000-08-02 | Smithkline Beecham Corp | Procedimiento para preparar eprosartano y compuestos intermediarios. |
| AR011125A1 (es) * | 1997-02-14 | 2000-08-02 | Smithkline Beecham Corp | Procedimiento para preparar eprosartano |
| US20030045561A1 (en) * | 2001-02-06 | 2003-03-06 | Smithkline Beecham Corporation | Method of treating isolated systolic hypertension |
| ZA984421B (en) * | 1997-05-27 | 1998-11-27 | Smithkline Beecham Corp | Method of treating isolated systolic hypertension |
| US6262102B1 (en) | 1997-06-27 | 2001-07-17 | Smithkline Beecham Corporation | Eprosartan monohydrate |
| WO1999007365A1 (en) * | 1997-08-06 | 1999-02-18 | Smithkline Beecham Corporation | Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation |
| US6630498B2 (en) | 1997-08-06 | 2003-10-07 | Smithkline Beecham Corporation | Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation |
| HUP0004407A3 (en) * | 1997-11-17 | 2002-03-28 | Smithkline Beecham Corp | Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture |
| US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| ZA991922B (en) * | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
| CN1198591C (zh) * | 1998-07-20 | 2005-04-27 | 史密丝克莱恩比彻姆公司 | 在口服固体剂型中包含依普沙坦的生物利用度提高的制剂 |
| ATE288900T1 (de) | 1998-07-24 | 2005-02-15 | Bayer Cropscience Ag | Substituierte benzoylcyclohexandione |
| DE19920791A1 (de) * | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
| DE19921424A1 (de) | 1999-05-08 | 2000-11-09 | Bayer Ag | Substituierte Benzoylketone |
| DE19946853A1 (de) | 1999-09-30 | 2001-04-05 | Bayer Ag | Substituierte Arylketone |
| DE10004084A1 (de) * | 2000-01-31 | 2001-08-02 | Bayer Ag | Substituierte Imid-Derivate |
| DE10221121A1 (de) * | 2002-05-13 | 2003-12-04 | Bayer Cropscience Ag | N'-Cyano-N-methyl-imidamid-Derivate |
| BR0313593A (pt) | 2002-08-19 | 2005-07-12 | Pfizer Prod Inc | Terapia de combinação para doenças hiperproliferativas |
| OA13174A (en) * | 2003-05-30 | 2006-12-13 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as HMG-Co inhibitors. |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| PL1673107T3 (pl) * | 2003-10-10 | 2008-06-30 | Abbott Laboratories Gmbh | Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II |
| US20060099230A1 (en) * | 2004-11-10 | 2006-05-11 | Chin-Chih Chiang | Novel formulations of eprosartan with enhanced bioavailability |
| EP1819681B1 (en) * | 2004-11-23 | 2009-08-12 | Warner-Lambert Company LLC | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| EP1752450A1 (en) | 2005-08-01 | 2007-02-14 | Merck Sante | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| WO2007054896A1 (en) * | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US20090270474A1 (en) * | 2005-12-06 | 2009-10-29 | Keiichi Shibagaki | Therapeutic Agent for Keratoconjunctival Disorder |
| WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
| WO2008010087A2 (en) * | 2006-07-14 | 2008-01-24 | Ranbaxy Laboratories Limited | Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof |
| US20080014263A1 (en) * | 2006-07-17 | 2008-01-17 | Glenmark Pharmaceuticals Limited | Amorphous eprosartan mesylate and process for the preparation thereof |
| CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
| US20100137613A1 (en) * | 2006-12-27 | 2010-06-03 | Hetero Drugs Limited | Process for eprosartan |
| US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009013760A2 (en) * | 2007-07-25 | 2009-01-29 | Hetero Drugs Limited | Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan |
| EP2295430A3 (en) * | 2007-07-25 | 2011-08-03 | Hetero Drugs Limited | Crystalline solid of eprosartan acetate |
| JP2011500783A (ja) * | 2007-10-22 | 2011-01-06 | オーキッド リサーチ ラボラトリーズ リミテッド | ヒストンデアセチラーゼ阻害剤 |
| WO2009084028A2 (en) * | 2007-12-03 | 2009-07-09 | Neuland Laboratories Ltd | Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate |
| CN101215284B (zh) * | 2007-12-31 | 2010-10-13 | 浙江华海药业股份有限公司 | 一种改进的依普罗沙坦的制备方法 |
| US20110054186A1 (en) * | 2008-03-31 | 2011-03-03 | Hetero Research Foundation | Process for eprosartan intermediate |
| AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| CN101333216A (zh) * | 2008-08-03 | 2008-12-31 | 浙江华海药业股份有限公司 | 一种新的依普罗沙坦甲磺酸盐成盐工艺 |
| US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
| WO2011004384A2 (en) | 2009-06-05 | 2011-01-13 | Glochem Industries Limited | Process for the preparation of eprosartan |
| WO2011051975A1 (en) | 2009-10-30 | 2011-05-05 | Matrix Laboratories Ltd | An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts |
| JP5815552B2 (ja) | 2009-12-08 | 2015-11-17 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 眼疾患を治療する化合物および方法 |
| RU2525156C2 (ru) * | 2010-07-15 | 2014-08-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2846387C (en) | 2011-08-26 | 2016-02-09 | Wockhardt Limited | Methods for treating cardiovascular disorders |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| JP2016516804A (ja) | 2013-04-17 | 2016-06-09 | ファイザー・インク | 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体 |
| AU2014274812B2 (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| EP3025711B1 (en) | 2013-07-23 | 2020-11-18 | Daiichi Sankyo Company, Limited | Medicine for preventing or treating hypertension |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| JP6934859B2 (ja) | 2016-03-24 | 2021-09-15 | 第一三共株式会社 | 腎疾患の治療のための医薬 |
| CA3103599A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition |
| AU2020209215B2 (en) | 2019-01-18 | 2023-02-02 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| JPS58157768A (ja) * | 1982-03-16 | 1983-09-19 | Takeda Chem Ind Ltd | ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体 |
| US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| DE69033469T2 (de) * | 1989-06-14 | 2000-09-07 | Smithkline Beecham Corp., Philadelphia | Imidazoalkensäure |
| CA2027937A1 (en) * | 1989-10-25 | 1991-04-26 | Richard M. Keenan | Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles |
| GB9027197D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027209D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027208D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027210D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| AU9137791A (en) * | 1990-12-14 | 1992-07-08 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| ES2130170T3 (es) * | 1990-12-14 | 1999-07-01 | Smithkline Beecham Corp | Composiciones bloqueantes del receptor de la angiotensina ii. |
| GB9027198D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027211D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027201D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027212D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027199D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027200D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
-
1991
- 1991-08-14 US US07/746,262 patent/US5185351A/en not_active Expired - Lifetime
-
1992
- 1992-08-12 CA CA002115170A patent/CA2115170C/en not_active Expired - Lifetime
- 1992-08-12 EP EP92918356A patent/EP0641203B1/en not_active Expired - Lifetime
- 1992-08-12 DE DE69232817T patent/DE69232817T2/de not_active Expired - Lifetime
- 1992-08-12 CZ CZ94311A patent/CZ281635B6/cs not_active IP Right Cessation
- 1992-08-12 AU AU24756/92A patent/AU667824B2/en not_active Ceased
- 1992-08-12 JP JP5504405A patent/JPH07500579A/ja active Pending
- 1992-08-12 UA UA94021675A patent/UA40587C2/uk unknown
- 1992-08-12 AT AT92918356T patent/ATE226073T1/de active
- 1992-08-12 RO RO94-00225A patent/RO113643B1/ro unknown
- 1992-08-12 ES ES92918356T patent/ES2185617T3/es not_active Expired - Lifetime
- 1992-08-12 HU HU9400413A patent/HU225048B1/hu unknown
- 1992-08-12 SK SK135-94A patent/SK281252B6/sk not_active IP Right Cessation
- 1992-08-12 WO PCT/US1992/006734 patent/WO1993003722A1/en not_active Ceased
- 1992-08-12 DK DK92918356T patent/DK0641203T3/da active
- 1992-08-12 PL PL92302397A patent/PL177234B1/pl unknown
- 1992-08-12 RU RU94018226A patent/RU2124513C1/ru active
- 1992-08-12 BR BR9206443A patent/BR9206443A/pt not_active IP Right Cessation
- 1992-08-13 MA MA22915A patent/MA22626A1/fr unknown
- 1992-08-14 CN CN92110883A patent/CN1036396C/zh not_active Expired - Lifetime
- 1992-08-14 ZA ZA926133A patent/ZA926133B/xx unknown
- 1992-08-14 MX MX9204737A patent/MX9204737A/es active IP Right Grant
- 1992-08-14 AP APAP/P/1992/000416A patent/AP525A/en active
- 1992-08-14 NZ NZ243966A patent/NZ243966A/en unknown
- 1992-08-14 IL IL10281392A patent/IL102813A/en not_active IP Right Cessation
- 1992-08-14 AP APAP/P/1995/000742A patent/AP527A/en active
- 1992-08-14 MY MYPI92001466A patent/MY110205A/en unknown
- 1992-08-14 PT PT100779A patent/PT100779B/pt not_active IP Right Cessation
- 1992-08-14 AP APAP/P/1995/000741A patent/AP526A/en active
- 1992-08-20 TW TW081106595A patent/TW234690B/zh not_active IP Right Cessation
-
1994
- 1994-02-10 OA OA60471A patent/OA09884A/en unknown
- 1994-02-11 NO NO940476A patent/NO305172B1/no not_active IP Right Cessation
- 1994-02-11 FI FI940642A patent/FI114796B/fi not_active IP Right Cessation
- 1994-02-11 BG BG98454A patent/BG61593B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY110205A (en) | Imidazolyl-alkenoic acids. | |
| PH27592A (en) | Imidazolyl-alkenoic acids and its method of use | |
| EP0403158A3 (en) | Imidazolyl-alkenoic acids | |
| AU640417B2 (en) | Substituted 5-((tetrazolyl)alkenyl)imidazoles | |
| EP0437103A3 (en) | Substituted 5-(alkyl)carboxamide imidazoles | |
| MY106159A (en) | Substituted n-(imidazolyl)alkyl alanine derivatives. | |
| WO1992020651A3 (en) | N-(heteroaryl)-imidazolyl-alkenoic acids | |
| MY106292A (en) | (alpha)-adrenergic receptor antagonists. |